{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:28:36Z","timestamp":1784147316748,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kyowa Hakko Kirin Co. Ltd."}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.diabres.2016.04.034","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T21:14:29Z","timestamp":1461964469000},"page":"244-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial"],"prefix":"10.1016","volume":"116","author":[{"given":"Masanori","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masari","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsukou","family":"Tei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinami","family":"Nagura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumito","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoe","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2016.04.034_b0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/138920011794520053","article-title":"Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice","volume":"12","author":"Abe","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.diabres.2016.04.034_b0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrneph.2015.38","article-title":"Haemodialysis-induced hypoglycaemia and glycaemic disarrays","volume":"11","author":"Abe","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.diabres.2016.04.034_b0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1507\/endocrj.K09E-318","article-title":"Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis","volume":"57","author":"Abe","year":"2010","journal-title":"Endocr J"},{"key":"10.1016\/j.diabres.2016.04.034_b0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/14656560903530683","article-title":"Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis","volume":"11","author":"Abe","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabres.2016.04.034_b0025","first-page":"S62","article-title":"Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","author":"Kidney Disease Outcomes Quality Initiative ((KDOQI))","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2016.04.034_b0030","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2016.04.034_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14656566.2013.761690","article-title":"The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis","volume":"14","author":"Fujii","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabres.2016.04.034_b0040","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1507\/endocrj.EJ11-0025","article-title":"The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis","volume":"58","author":"Ito","year":"2011","journal-title":"Endocr J"},{"key":"10.1016\/j.diabres.2016.04.034_b0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11255-013-0552-6","article-title":"Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes","volume":"46","author":"Otsuki","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.diabres.2016.04.034_b0050","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10157-015-1110-6","article-title":"Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases","volume":"19","author":"Inoue","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.diabres.2016.04.034_b0055","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/hdi.12312","article-title":"The Glycemic Indices in Dialysis Evaluation (GIDE) study: comparative measures of glycemic control in diabetic dialysis patients","volume":"19","author":"Williams","year":"2015","journal-title":"Hemodial Int"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2016.04.034_b9000","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1744-9987.12299","article-title":"Best practice for diabetic patients on hemodialysis 2012","volume":"19","author":"Nakao","year":"2015","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.diabres.2016.04.034_b0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.ajkd.2015.09.010","article-title":"Levocarnitine improves cardiac function in hemodialysis patients with left ventricular hypertrophy: a randomized controlled trial","volume":"67","author":"Higuchi","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabres.2016.04.034_b0065","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1742-1241.2011.02812.x","article-title":"Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study","volume":"65","author":"Nowicki","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2016.04.034_b0070","doi-asserted-by":"crossref","first-page":"840","DOI":"10.4239\/wjd.v6.i6.840","article-title":"Diabetes therapies in hemodialysis patients: dipeptidase-4 inhibitors","volume":"6","author":"Nakamura","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.diabres.2016.04.034_b0075","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial","volume":"38","author":"Udell","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.04.034_b0080","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.2337\/dc14-0865","article-title":"The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications","volume":"37","author":"Avogaro","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.04.034_b0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.metabol.2012.09.004","article-title":"A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients","volume":"62","author":"Satoh-Asahara","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2016.04.034_b0090","first-page":"1","article-title":"Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes","author":"Anderson","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.diabres.2016.04.034_b0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrneph.2013.12","article-title":"Noninsulin glucose-lowering agents for the treatment of patients on dialysis","volume":"9","author":"Flynn","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.diabres.2016.04.034_b0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000380974","article-title":"DPP-4 inhibitors in diabetic patients with chronic kidney disease and end-stage kidney disease on dialysis in clinical practice","volume":"185","author":"Abe","year":"2015","journal-title":"Contrib Nephrol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716300985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716300985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T09:06:41Z","timestamp":1655629601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716300985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":21,"alternative-id":["S0168822716300985"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2016.04.034","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2016.04.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}